AP NEWS

Retinopathy of Prematurity - 2018 Pipeline Insight Featuring Biomar Microbial Technologies, F. Hoffmann-La Roche, Recordati, Radikal Therapeutics, EyeGene, and Insmed - ResearchAndMarkets.com

December 17, 2018

DUBLIN--(BUSINESS WIRE)--Dec 17, 2018--The “Retinopathy of Prematurity - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Retinopathy of Prematurity development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

The report assesses the active Retinopathy of Prematurity pipeline products by developmental stage, product type, molecule type, and administration route.

Scope

The report provides a snapshot of the pipeline development for Retinopathy of Prematurity The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for Retinopathy of Prematurity The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Retinopathy of Prematurity The report also covers the dormant and discontinued pipeline projects related to Retinopathy of Prematurity

Key Topics Covered

1. Report Introduction

2. Retinopathy of Prematurity Overview

3. Pipeline Therapeutics

An Overview of Pipeline Products for Retinopathy of Prematurity

4. Comparative Analysis

5. Products in Clinical Stage 5.1 Drug Name : Company Name

Product Description Research and Development Product Development Activities

6. Products in Pre-Clinical and Discovery Stage 6.1 Drug Name : Company Name

Product Description Research and Development Product Development Activities

7. Therapeutic Assessment

Assessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type

8. Inactive Products 8.1 Drug Name : Company Name

Product Description Research and Development Product Development Activities

Companies Featured

Biomar Microbial Technologies F. Hoffmann-La Roche Ltd. Recordati SpA Radikal Therapeutics EyeGene Insmed

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/qg2n59/retinopathy_of?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181217005433/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Optical Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH OPTICAL PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/17/2018 09:27 AM/DISC: 12/17/2018 09:27 AM

http://www.businesswire.com/news/home/20181217005433/en

AP RADIO
Update hourly